BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive LeukemiaMatthew S. Zabriskie, Thomas O’Hare, H. Jean Khoury et al.|Cancer Cell|2014Cited by 366
Deciphering the molecular mechanism of FLT3 resistance mutationsPanagiota S. Georgoulia, Ran Friedman|FEBS Journal|2020Cited by 26
Resistance to FLT3 inhibitors involves different molecular mechanisms and reduces new DNA synthesisJingmei Yang, Ran Friedman|Biochemistry and Biophysics Reports|2025Cited by 2